Article Top Ad

Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – July 6, 2022) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Company” or “Innocan”) is pleased to announce positive results in a preclinical trial involving a dog with refractory (drug-resistant) epilepsy. In this trial, the dog was treated with Innocan Pharma’s LPT (CBD Loaded Liposome Platform) injections. The results demonstrated that the frequency and the intensity of the dog’s epileptic seizures decreased significantly.

The dog in the study is Paco, which is a 9 year-old intact male cane corso dog with a body weight of 47 kg. Paco suffered from refractory idiopathic (drug-resistant) epilepsy. Paco was treated with two anti-epileptic drugs but was still suffering from seizures several times a month. Paco was administered several injections of the LPT drug with a 4-week interval between injections. Since the last LPT injection on April 25, 2022, Paco has not suffered from any seizures i.e., over 10 weeks to date.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/130160

Powered by WPeMatico